Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality - Top-Institutions - MDSpire

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

  • By

  • Joaquín Martínez-López

  • María-Victoria Mateos

  • Cristina Encinas

  • Anna Sureda

  • José Ángel Hernández-Rivas

  • Ana Lopez de la Guía

  • Diego Conde

  • Isabel Krsnik

  • Elena Prieto

  • Rosalía Riaza Grau

  • Mercedes Gironella

  • María Jesús Blanchard

  • Nerea Caminos

  • Carlos Fernández de Larrea

  • María Alicia Senin

  • Fernando Escalante

  • José Enrique de la Puerta

  • Eugenio Giménez

  • Pilar Martínez-Barranco

  • Juan José Mateos

  • Luis Felipe Casado

  • Joan Bladé

  • Juan José Lahuerta

  • Javier de la Cruz

  • Jesús San-Miguel

  • October 19, 2020

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Infectious Diseases

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Immunology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Infectious Diseases

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Infectious Diseases
    • Oncology

Original Source(s)

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

  • by Joaquín Martínez-López, María-Victoria Mateos, Cristina Encinas, Anna Sureda, José Ángel Hernández-Rivas, Ana Lopez de la Guía, Diego Conde, Isabel Krsnik, Elena Prieto, Rosalía Riaza Grau, Mercedes Gironella, María Jesús Blanchard, Nerea Caminos, Carlos Fernández de Larrea, María Alicia Senin, Fernando Escalante, José Enrique de la Puerta, Eugenio Giménez, Pilar Martínez-Barranco, Juan José Mateos, Luis Felipe Casado, Joan Bladé, Juan José Lahuerta, Javier de la Cruz, Jesús San-Miguel

  • October 19, 2020

Related Content

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy